Loading…
Boston Scientific announced a recommended offer to acquire BTG plc, a UK-based company specializing in minimally-invasive treatments for cancer and vascular diseases, for approximately £3.3 billion ($4.2 billion). The transaction is expected to close in the first half of 2019.
“Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc.”news.bostonscientific.com
Summarized from public sources; check the original articles before acting on it.